Nasdaq |
AstraZeneca: FDA Panel Mostly Favorable in Diabetes Treatment Vote
Nasdaq LONDON–AstraZeneca PLC (AZN.LN) Wednesday said most members of a U.S. Food and Drug Administration committee found its diabetes treatment saxagliptin has an acceptable cardiovascular risk profile. The drug company said 13 of the 15 … AstraZeneca : FDA Panel Reviews Savor Study Results For Onglyza …RTT News AstraZeneca Drug Gets US Orphan Designation, Key Cancer Drug Study BackedLondon South East AstraZeneca share price: Immuno-oncology therapy granted orphan drug statusiNVEZZ all 84 news articles » |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.